Jinwon Life Sciences Administers First Clinical Trial Subject for COVID-19 Infection Prevention Treatment
[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 11th that it administered GLS-1200, a novel coronavirus (COVID-19) infection prevention nasal spray treatment approved for Phase 2 clinical trials by the U.S. Food and Drug Administration (FDA), to the first clinical trial participant at the University of Pennsylvania Clinical Research Center.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- "Am I Really in the Top 30%?" and "Worried About My Girlfriend in the Bottom 70%"... Buzz Over High Oil Price Relief Fund
- The Unexpected Story of an American Man Who Won the Lottery 18 Times in 29 Years: "My Real Luck Is My Wife"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
According to a company official, "After receiving FDA approval for the Phase 2 clinical trial at the end of April, the study completed the Institutional Review Board (IRB) approval process at the University of Pennsylvania Clinical Research Center, leading to the administration to the first clinical trial participant. Currently, recruitment of clinical trial participants is progressing smoothly, so the dosing for 225 participants is expected to proceed without any issues."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
